Joyoti Dey, Ph.D.
Affiliations: | 2012 | Molecular and Cellular Biology | University of Washington, Seattle, Seattle, WA |
Google:
"Joyoti Dey"Mean distance: 23748
Parents
Sign in to add mentor| James M. Olson | grad student | 2012 | University of Washington | |
| (Understanding the role of the Sonic Hedgehog signaling pathway in cerebellar development and medulloblastoma genesis.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Jang SC, Economides KD, Moniz RJ, et al. (2021) ExoSTING, an extracellular vesicle loaded with STING agonists, promotes tumor immune surveillance. Communications Biology. 4: 497 |
| Gundle KR, Deutsch GB, Goodman HJ, et al. (2020) Multiplexed evaluation of microdosed antineoplastic agents in situ in the tumor microenvironment of patients with soft tissue sarcoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Hatton BA, Grenley M, Garnsey J, et al. (2019) Abstract 4136: Direct intratumoral microdosing via the CIVO® platform reveals anti-tumor immune responses induced by the SUMO inhibitor TAK-981 Cancer Research. 79: 4136-4136 |
| Brabetz S, Leary SES, Gröbner SN, et al. (2018) A biobank of patient-derived pediatric brain tumor models. Nature Medicine |
| Dey J, Deckwerth TL, Kerwin WS, et al. (2017) Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition. Scientific Reports. 7: 18007 |
| Dey J, Kerwin WS, Grenley MO, et al. (2016) A Platform for Rapid, Quantitative Assessment of Multiple Drug Combinations Simultaneously in Solid Tumors In Vivo. Plos One. 11: e0158617 |
| Dey J, Kerwin W, Casalini J, et al. (2016) Voruciclib Sensitizes High Risk Diffuse Large B Cell Lymphoma to BCL2 Inhibition Mediated Cell Death and Tumor Regression Blood. 128: 4167-4167 |
| Dey J, Casalini J, Ditzler S, et al. (2016) Abstract 2835: Voruciclib, a clinical stage oral CDK inhibitor, sensitizes triple negative breast cancer xenografts to proteasome inhibition Cancer Research. 76: 2835-2835 |
| Chen N, Brachmann C, Liu X, et al. (2015) Albumin-bound nanoparticle (nab) paclitaxel exhibits enhanced paclitaxel tissue distribution and tumor penetration. Cancer Chemotherapy and Pharmacology |
| Klinghoffer RA, Bahrami SB, Hatton BA, et al. (2015) A technology platform to assess multiple cancer agents simultaneously within a patient's tumor. Science Translational Medicine. 7: 284ra58 |